- Home
- RXRX vs RXST Comparison
RXRX vs RXST Comparison
Compare RXRX & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- RXST
- Stock Information
- Founded
- RXRX 2013
- RXST 1997
- Country
- RXRX United States
- RXST United States
- Employees
- RXRX N/A
- RXST N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RXRX Health Care
- RXST Health Care
- Exchange
- RXRX Nasdaq
- RXST Nasdaq
- Market Cap
- RXRX 2.6B
- RXST 307.3M
- IPO Year
- RXRX 2021
- RXST 2021
- Fundamental
- Price
- RXRX $4.50
- RXST $9.61
- Analyst Decision
- RXRX Buy
- RXST Hold
- Analyst Count
- RXRX 4
- RXST 11
- Target Price
- RXRX $7.25
- RXST $12.00
- AVG Volume (30 Days)
- RXRX 68.2M
- RXST 691.2K
- Earning Date
- RXRX 11-05-2025
- RXST 11-05-2025
- Dividend Yield
- RXRX N/A
- RXST N/A
- EPS Growth
- RXRX N/A
- RXST N/A
- EPS
- RXRX N/A
- RXST N/A
- Revenue
- RXRX $43,689,000.00
- RXST $142,085,000.00
- Revenue This Year
- RXRX $24.17
- RXST N/A
- Revenue Next Year
- RXRX $20.96
- RXST $6.71
- P/E Ratio
- RXRX N/A
- RXST N/A
- Revenue Growth
- RXRX N/A
- RXST 10.75
- 52 Week Low
- RXRX $3.79
- RXST $6.32
- 52 Week High
- RXRX $12.36
- RXST $55.57
- Technical
- Relative Strength Index (RSI)
- RXRX 35.66
- RXST 58.72
- Support Level
- RXRX $5.58
- RXST $7.99
- Resistance Level
- RXRX $5.76
- RXST $9.98
- Average True Range (ATR)
- RXRX 0.42
- RXST 0.57
- MACD
- RXRX -0.20
- RXST 0.07
- Stochastic Oscillator
- RXRX 10.52
- RXST 65.33
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.